viral suppression

Related by string. Viral Suppression * Viral . VIRAL . Virals . virals : viral loads . inhibit viral replication . viral infection . viral load . viral infections . contagious viral infection . undetectable viral load / Suppression . suppressions : wildfire suppression . bone marrow suppression . bloody suppression . ruthless suppression . brutal suppression . immune suppression * *

Related by context. All words. (Click for frequent words.) 73 virologic response 71 undetectable viral load 70 viral load 69 HBV DNA 69 virologic failure 69 sustained virologic response 69 virologic suppression 68 virological response 67 undetectable viral loads 67 adefovir 67 lamivudine 66 HBeAg seroconversion 66 seroconversion 66 HCV RNA 66 antiviral activity 66 virological suppression 65 adalimumab 65 raltegravir 65 sustained virological response 65 viral loads 65 entecavir 65 antiretroviral therapy 64 HIV RNA 64 protease inhibitor PI 64 darunavir 64 antiviral efficacy 64 virologic 64 tipranavir 64 fosamprenavir 64 complete cytogenetic response 63 nelfinavir 63 telbivudine 63 complete remissions 63 virologic responses 63 viremia 63 HAART 63 antiretroviral therapy ART 63 copies mL 63 cART 63 tumor regression 63 ritonavir boosted 63 APTIVUS r 63 TDF FTC 62 HAART regimens 62 HAART regimen 62 LEXIVA r 62 antibody titers 62 CD4 counts 62 infliximab 62 NRTI 62 antiretroviral naive 62 peginterferon 62 immune reconstitution 62 virological failure 62 low dose ritonavir 61 lopinavir ritonavir 61 nitazoxanide 61 darunavir ritonavir 61 antibody responses 61 copies ml 61 HBV DNA levels 61 atazanavir 61 virologic breakthrough 61 peg interferon 61 NNRTIs 61 NNRTI resistance 61 experienced virologic failure 61 log# reduction 61 peginterferon alfa 2a 61 enfuvirtide 61 NNRTI 61 DAPT 61 antiretroviral regimen 61 viral kinetics 61 imatinib therapy 61 CD4 + cell 61 pyrazinamide 61 lopinavir 61 VIRAMUNE 61 vicriviroc 60 rapid virologic response 60 chlorambucil 60 abacavir lamivudine 60 complete cytogenetic 60 PREZISTA r 60 decitabine 60 antiviral therapy 60 HBeAg 60 potent antiretroviral therapy 60 seroprotection 60 imatinib 60 mg dose 60 tumor regressions 60 paricalcitol 60 genotypic resistance 60 ribavirin RBV 60 CD4 cell 60 clodronate 60 serum HBV DNA 60 undetectable HCV RNA 60 APTIVUS 60 durable remissions 59 Pegasys plus Copegus 59 HCV infected 59 mucosal healing 59 mcg dose 59 dose ritonavir 59 mycophenolate mofetil 59 d4T 59 virologically 59 dosing interval 59 tiotropium 59 plasma concentrations 59 mg kg dose 59 anti leukemic 59 TMC# [001] 59 tapentadol ER 59 platelet counts 59 rilpivirine 59 pegylated interferon 59 undetectable HBV DNA 59 certolizumab 59 HbA1c levels 59 HCV genotype 1 59 AZT zidovudine Retrovir 59 #mg dose [002] 59 Telbivudine 59 mg BID 59 fondaparinux 59 CMV infection 59 antiretroviral regimens 59 fluvastatin 59 HBeAg positive patients 59 pCR 59 insulin detemir 59 cytogenetic response 59 protease inhibitor 59 LPV r 58 mg QD 58 CMV disease 58 comparator PI r 58 tenofovir emtricitabine 58 atazanavir ritonavir 58 NRTIs 58 cidofovir 58 ibandronate 58 zidovudine 58 ribavirin therapy 58 plasma uric acid 58 Hydroxyurea 58 nephrotoxicity 58 PRT# 58 steroid dexamethasone 58 seropositive patients 58 pegIFN 58 nadolol 58 unboosted 58 PASI scores 58 ACR# response 58 tumor shrinkage 58 alfa 2a 58 platelet reactivity 58 Valcyte 58 antitumor activity 58 oral bioavailability 58 administered subcutaneously 58 nevirapine Viramune 58 peg IFN 58 zoledronic acid 58 cytogenetic responses 58 PrEP 58 Peg IFN 58 docetaxel chemotherapy 58 bronchodilation 58 Vacc 4x 58 CIMZIA TM 58 A1c levels 58 divalproex sodium 58 immunosuppression 58 protease inhibitors PIs 58 annualized relapse 58 bezafibrate 58 ISENTRESS 58 antiviral potency 58 solifenacin 58 PROMACTA 57 response CCyR 57 placebo 57 serum HCV RNA 57 zidovudine lamivudine 57 fluconazole 57 IDX# 57 fulvestrant 57 platelet inhibition 57 Darunavir 57 dapsone 57 efavirenz Sustiva 57 combination antiretroviral therapy 57 plasma HCV RNA 57 cabazitaxel 57 dosage regimens 57 interferon therapy 57 plus ribavirin 57 boosted protease inhibitor 57 gout flares 57 #mg dose [001] 57 TMC# r 57 ciclosporin 57 BARACLUDE 57 pomalidomide 57 teriflunomide 57 urate lowering therapy 57 CANCIDAS 57 stavudine 57 stavudine d4T 57 nucleotide analog 57 PREZISTA rtv 57 tolerability 57 indinavir 57 disease progression 57 tamoxifen therapy 57 radiographic progression 57 tolerability profile 57 trastuzumab Herceptin ® 57 amprenavir 57 tipranavir r 57 adefovir dipivoxil 57 lopinavir r 57 degarelix 57 viraemia 57 AGILECT R 57 CD4 + T 57 isoniazid 57 systemic absorption 57 interferon alfa 57 SIV infection 57 Pegasys ® 57 immunological responses 57 alteplase 57 INTELENCE 57 SVR# 57 PegIFN RBV 57 A1C levels 57 topotecan 57 plasma viremia 57 SCIg 57 pegylated interferon alfa 57 abatacept 57 nilotinib 57 ABC/3TC 57 bisphosphonate therapy 57 pegylated liposomal doxorubicin 57 d4T stavudine Zerit 57 ribavirin 57 valacyclovir 57 3TC lamivudine Epivir 56 serum clusterin levels 56 tenofovir 56 bosentan 56 peak plasma concentrations 56 atazanavir sulfate 56 dose limiting toxicities 56 dosing regimens 56 posaconazole 56 nucleoside naive 56 remission CR 56 ritonavir 56 BARACLUDE ® 56 CCyR 56 IFN alpha 56 interferon ribavirin 56 NPH insulin 56 APTIVUS R 56 neutrophil counts 56 LEXIVA 56 exemestane 56 suppressive therapy 56 clinically meaningful improvement 56 IFN beta 56 BRAF mutation 56 HBsAg 56 gemifloxacin 56 MCyR 56 caspofungin 56 ritonavir boosted lopinavir 56 mitoxantrone 56 Kaplan Meier analysis 56 hepatitis C virus 56 virologically suppressed 56 rituximab 56 etanercept 56 GnRH agonist 56 hour bronchodilation 56 peginterferon ribavirin 56 atazanavir Reyataz 56 HIV infection 56 peginterferon alfa 2b 56 favorable tolerability 56 plus dexamethasone 56 desvenlafaxine succinate 56 ropinirole 56 darunavir r 56 bortezomib 56 mcg BID 56 pharmacokinetic characteristics 56 engraftment 56 undetectable viral 56 NRTI backbone 56 mesalamine granules 56 glatiramer acetate 56 Traficet EN 56 bevirimat 56 androgen deprivation 56 monotherapy 56 tolvaptan 56 corticosteroid therapy 56 dose colchicine 56 dose cohorts 56 neutralizing antibodies 56 clinically meaningful 56 trastuzumab 56 calcitriol 56 ARV therapy 56 serum potassium 56 antibody titer 56 NAbs 56 zidovudine AZT 56 Aptivus ® 56 IU mL 56 REYATAZ R 56 APTIVUS ritonavir 56 PegIFN 56 saquinavir 56 imipenem 56 rFIXFc 56 sirolimus 56 CCR5 antagonist 56 aminotransferases 56 Virologic failure 56 tenofovir Viread 56 GnRH antagonist 56 CD4 T 56 active antiretroviral therapy 56 lymphocyte counts 56 anticoagulation 56 Natalizumab 56 dose cytarabine 56 chemoradiotherapy 56 apremilast 56 mg RDEA# 56 antitumor effect 56 detectable HCV RNA 56 dose titration 56 serum phosphate 56 hepatitis C genotype 56 rhGH 56 serum urate levels 56 Elitek 55 immunosuppressive agents 55 lanthanum carbonate 55 rindopepimut 55 pramipexole 55 Hepsera 55 chronic HCV infection 55 acute gout flares 55 myelosuppression 55 pharmacokinetic interactions 55 FOLFOX6 55 Pegylated Interferon 55 relapsed MM 55 lamivudine refractory patients 55 intravenous IV infusion 55 radezolid 55 interferon alfa 2b 55 glycated hemoglobin levels 55 alpha 2a 55 integrase inhibitor 55 transgene expression 55 liver histology 55 alanine aminotransferase ALT 55 antiretroviral drugs 55 oxcarbazepine 55 anastrozole 55 daunorubicin 55 rifapentine 55 refractory gout 55 ertapenem 55 rt PA 55 plus MTX 55 pioglitazone 55 elotuzumab 55 iPrEx study 55 IFN α 55 receiving APTIVUS r 55 HSCT 55 lopinavir r arm 55 dose regimen 55 COPD exacerbations 55 Raltegravir 55 co trimoxazole 55 pegylated interferon alpha 55 olmesartan 55 null responders 55 serum phosphate levels 55 mcg doses 55 dacarbazine 55 FluCAM 55 glucocorticoid 55 mg doses 55 μg dose 55 tenofovir DF 55 octreotide LAR 55 lipid lowering therapy 55 Adalimumab 55 dexamethasone Decadron 55 β blockers 55 partial remissions 55 EXJADE 55 CD4 + 55 inecalcitol 55 hematologic toxicity 55 lopinavir ritonavir Kaletra 55 rapid virological response 55 docetaxel 55 dose regimens 55 COPEGUS 55 mg TID 55 ALT flares 55 lumbar spine BMD 55 nucleoside analogues 55 antiretroviral treatment 55 nucleoside naive patients 55 imipramine 55 severe neutropenia 55 dose cyclophosphamide 55 pegylated interferon alfa 2a 55 esomeprazole 55 timepoint 55 bendamustine 55 IELT 55 cobicistat 55 teriparatide 55 relapsing MS 55 rFVIIa 55 evaluable subjects 55 oxycodone CR 55 amoxicillin clavulanate 55 antidepressant therapy 55 BYSTOLIC 55 INCB# [001] 55 plus methotrexate 55 serum phosphorus 55 maraviroc 55 hepatic fibrosis 55 EGFR inhibitors 55 avosentan 55 renal function 55 selegiline 55 neurologic progression 55 opioid analgesia 55 trimethoprim sulfamethoxazole 55 CR nPR 55 achieved ACR# 55 virologic response EVR 55 quetiapine 55 elvitegravir 55 Dasatinib 55 HBeAg positive 55 serum urate 55 antiretroviral ARV therapy 55 Doxil ® 55 HIV seroconversion 55 abacavir 55 splenectomized patients 55 plasma pharmacokinetics 55 cytotoxicity 55 moxifloxacin 55 NATRECOR ® 55 baminercept 55 pegfilgrastim 55 taxane chemotherapy 55 intravenous bisphosphonates 55 etravirine 55 mRCC 55 FUZEON 55 SCH # 55 Hematologic toxicity 55 ACTEMRA TM 55 dexmedetomidine 54 Bristol Myers Squibb Sustiva 54 DMARD 54 Pharmacokinetics PK 54 VA# [002] 54 severe rotavirus gastroenteritis 54 recurrent genital herpes 54 carvedilol 54 mcg kg 54 tipranavir ritonavir 54 pimecrolimus 54 ponatinib 54 recurrent VTE 54 Lamictal XR 54 doxorubicin docetaxel 54 Epivir 54 LVEF 54 ivabradine 54 tamsulosin 54 VIRAMUNE XR 54 canakinumab 54 ACZ# 54 bicalutamide 54 HPV-#/# 54 Copegus ribavirin 54 posttransplant 54 allopurinol 54 intravenous cyclophosphamide 54 pharmacokinetic profile 54 HBeAg negative patients 54 Fludara 54 dose cohort 54 Reverset 54 mg ustekinumab 54 iniparib 54 Cethromycin 54 EDSS scores 54 cardiac toxicity 54 omega interferon 54 goserelin 54 ARB telmisartan 54 N acetylcysteine 54 cangrelor 54 Gag polymorphisms 54 transcriptase inhibitors NNRTIs 54 viral kinetic 54 spontaneous preterm delivery 54 REYATAZ ® 54 dosing intervals 54 antitumor effects 54 alkylating agent 54 gefitinib 54 oral rivaroxaban 54 pyridostigmine 54 alendronate 54 active comparator 54 alicaforsen enema 54 glucose lowering 54 interferon IFN 54 venlafaxine 54 transcriptase inhibitor NNRTI 54 L dopa 54 Viread Emtriva 54 ULORIC 54 ispinesib administered 54 octreotide 54 FOLPI regimen 54 vandetanib 54 ketoconazole 54 NATRECOR R 54 #mg dose [003] 54 tenofovir FTC 54 antiretrovirals 54 nanomolar 54 FOLFOX4 54 EGFR TKI 54 risedronate 54 standard chemotherapy regimen 54 OADs 54 CLL cells 54 adrenal suppression 54 thalidomide dexamethasone 54 titers 54 sunitinib 54 nucleoside reverse transcriptase inhibitor 54 INFERGEN 54 antitumor responses 54 HBV infection 54 insulin degludec 54 aromatase inhibitor therapy 54 tocilizumab 54 FTC TDF 54 ovulation suppression 54 circulating lymphocytes 54 dosage regimen 54 uric acid lowering 54 platelet inhibitor 54 CIMZIA ™ 54 TPV r 54 Bcl xL 54 levodopa 54 mg/m2 dose 54 antiretroviral 54 dacetuzumab 54 ALND 54 oral FTY# 54 dose dexamethasone 54 dexamethasone 54 dosing frequency 54 antihypertensive therapy 54 doripenem 54 subcutaneously administered 54 8mg/kg 54 chlamydial infection 54 gemcitabine Gemzar 54 FOSRENOL ® 54 patients evaluable 54 Peginterferon 54 efavirenz emtricitabine 54 VIR# 54 sotalol 54 Free Survival PFS 54 coadministration 54 CR CRu 54 clinically meaningful efficacy 54 PREZISTA ritonavir 54 azathioprine 54 AZOR 54 dasatinib 54 LANTUS R 54 Phase #/#a 54 dosing regimen 54 FROVA 54 coinfected 54 NNRTI resistant virus 54 S/GSK# 54 neutralizing antibody 54 VELCADE melphalan 54 efavirenz EFV 54 Raptiva r 54 peginterferon alpha 2a 54 biologic DMARD 54 alpha blocker 54 adalimumab Humira 54 NLX P# 54 efavirenz 54 STELARA ® 53 protease inhibitors 53 investigational protease inhibitor 53 RoACTEMRA 53 Cimzia R 53 sitagliptin 53 prednisone prednisolone 53 argatroban 53 oblimersen 53 idarubicin 53 Betaferon ® 53 sUA 53 Sustiva efavirenz 53 peginterferon alfa 2a #KD 53 FOLPI 53 serum testosterone levels 53 paliperidone ER 53 anti TNF 53 unfractionated heparin 53 Cmax 53 ZOLINZA 53 CD4 cells 53 weekly subcutaneous injections 53 piperacillin tazobactam 53 bicifadine 53 #mg/day [002] 53 RLS symptoms 53 losartan 53 antihypertensive medications 53 enoxaparin 53 heavily pretreated patients 53 beta blocker therapy 53 intensive statin therapy 53 #mg BID [003] 53 pharmacokinetic properties 53 dosing schedules 53 Bezielle 53 KAPIDEX 53 placebo dexamethasone 53 tirofiban 53 pharmacodynamic profile 53 HbA1c 53 molindone 53 INVIRASE 53 CsA 53 GLYX 53 ziprasidone 53 renal toxicity 53 antiandrogens 53 riociguat 53 evaluable patients 53 heavily pretreated 53 NRTI resistance 53 FOLFIRINOX 53 recurrent glioblastoma multiforme 53 MIRCERA 53 favorable pharmacokinetic profile 53 potentiation 53 CD4s 53 interferon 53 boceprevir 53 antiretroviral medications 53 Interferon alpha 53 Bortezomib 53 GeoVax vaccine 53 intravenous diuretics 53 olanzapine 53 tolerability profiles 53 sulfadoxine pyrimethamine 53 tamoxifen 53 peginterferon alfa 53 rifamycins 53 HCV genotype 53 QT intervals 53 Cytoxan 53 ancrod 53 CCL#L# 53 chemo radiotherapy 53 montelukast 53 daily subcutaneous injections 53 rifampin 53 serum concentrations 53 elagolix 53 TNF inhibitor 53 parkinsonian symptoms 53 metreleptin 53 Phase 2a trial 53 ACR# responses 53 biochemical relapse 53 Sym# 53 Aptivus 53 verapamil 53 antithrombotic 53 serum calcium 53 HCV viral 53 tacrolimus 53 corrected QT interval 53 rimonabant #mg 53 intermittent dosing 53 REYATAZ r 53 serum testosterone 53 CIMZIA TM certolizumab pegol 53 immunogenicity 53 receiving prophylactic anticoagulation 53 nocturnal hypoglycaemia 53 RLAI 53 viral replication 53 q8h 53 preclinically 53 pregabalin 53 eptifibatide 53 cinacalcet 53 immunosuppressive regimens 53 statin therapy 53 CD8 responses 53 #mg QD [001] 53 Viral load 53 secondary efficacy endpoints 53 subcutaneous injections 53 dapagliflozin plus 53 #mg BID [001] 53 systemic toxicity 53 LATUDA 53 hsCRP levels 53 ascending dose 53 pimozide 53 FOXP3 53 timepoints 53 pharmacokinetic PK profile 53 rosuvastatin #mg 53 salmeterol fluticasone 53 glycemia 53 eculizumab therapy 53 low dose cytarabine 53 HCV replicon 53 hemoglobin Hb 53 definite stent thrombosis 53 dose proportionality 53 hemoglobin A1c levels 53 treatment regimens 53 IFN gamma 53 temsirolimus 53 QTc interval 53 chemotherapeutic regimens 53 HCV infection 53 Thal Dex 53 HCV 53 efficacy 53 invasive aspergillosis 53 progression TTP 53 natalizumab 53 TEAEs 53 DermaVir Patch 53 ALT normalization 53 QTcF 53 neostigmine 53 aldosterone antagonists 53 MS relapses 53 blood Phe levels 53 Q#IR 53 dosing cohorts 53 clopidogrel 53 metabolic parameters 53 anagrelide 53 micafungin 53 CYPHER Stent 53 Adefovir 53 interferon beta therapy 53 lacosamide 53 HbA1C 53 unfractionated heparin UFH 53 PSADT 53 TNF alpha antagonist 53 forodesine 53 MADRS score 53 hemoglobin concentrations 53 DMARDs 53 anemia hemoglobin 53 #mg/m# [001] 53 COPAXONE ® 53 rFSH 53 HAQ DI 53 telaprevir VX 53 noninferiority 53 p# activation 53 GAMMAGARD 53 PEG IFN 53 HCV SPRINT 53 Tindamax R 53 lamotrigine 53 serum phosphorous 53 antimicrobial prophylaxis 53 lymphopenia 53 baseline HbA1c 53 hyperalgesia 53 endoscopic remission 53 herpes infections 53 immune responses 53 inhibitor RG# 53 glargine 53 #mg QD [002] 53 abciximab 53 Hb A1C 53 NXL# 53 delayed CINV 53 Cisplatin 53 PEG Interferon lambda 53 abacavir Ziagen 53 iPTH 53 IBS symptoms 53 certolizumab pegol 53 hepatotoxicity 53 receiving VICTRELIS 53 COPAXONE R 53 RLY# 53 methotrexate 53 sinus rhythm 53 RRMS patients 53 systemically administered 53 Pegasys peginterferon alfa 2a 53 chronic hepatitis B. 53 visilizumab 53 Telaprevir 53 median PFS 53 limiting toxicity 53 Naive Patients 52 VAPRISOL 52 Imatinib 52 hypogonadal men 52 metastatic RCC 52 Androxal TM 52 mcg Albuferon 52 4mg/kg 52 creatinine clearance 52 aldosterone antagonist 52 HIV infected 52 pharmacodynamic properties 52 SELZENTRY 52 sUA levels 52 erlotinib 52 nephrotoxic drugs 52 ANA# 52 lispro 52 cisplatin chemotherapy 52 chlorthalidone 52 superinfection 52 AVODART 52 #mg doses [002] 52 captopril 52 iclaprim 52 nonnucleoside reverse transcriptase inhibitors 52 maximally tolerated dose 52 nicotinic acid 52 zoledronate 52 treprostinil 52 idraparinux 52 BENICAR HCT 52 Celecoxib 52 serum creatinine levels 52 mg simvastatin 52 median CD4 52 minocycline 52 Symadex 52 Combination therapy 52 IV bisphosphonates 52 CROI 52 morphometric vertebral fractures 52 immunomodulatory therapy 52 nucleoside analog 52 HCV genotypes 52 rHuPH# 52 nab paclitaxel 52 CRp 52 nucleoside 52 HCV RESPOND 2 52 CMV infections 52 neutralizing antibody responses 52 azacitidine 52 transaminase elevations 52 CD# upregulation 52 cells/mm3 52 anti HBs 52 genotypic 52 tenofovir gel 52 VFEND 52 Mylotarg 52 transdermal estradiol 52 nucleoside analogue 52 CCR5 tropic HIV 52 AMN# [001] 52 HBeAg negative 52 cardiovascular morbidity 52 potent antiviral 52 pertuzumab 52 hemoglobin concentration 52 polymerase inhibitor 52 viral titer 52 log# 52 antioxidant supplementation 52 Victoza ® 52 Lamivudine 52 telcagepant 52 epoetin beta 52 azithromycin 52 febrile neutropenia 52 nicardipine 52 locoregional disease 52 DFMO 52 glycemic control 52 retinal thickness 52 triamcinolone 52 PEG Intron 52 QTc prolongation 52 Sustained virologic response 52 lamivudine 3TC 52 Ritonavir 52 remyelination 52 aspartate aminotransferase 52 adjuvant tamoxifen 52 tumor necrosis 52 interferon beta 52 dosed orally 52 Kivexa 52 methotrexate monotherapy 52 fibrinolytic 52 reinfarction 52 molecular remissions 52 dose Iluvien 52 hemorrhagic complications 52 reperfusion therapy 52 Tekamlo 52 Durezol 52 interferon alfa 2a 52 rHuEPO 52 non progressors 52 placebo controlled trials 52 Pegylated interferon 52 cEVR 52 ALISTA 52 LMWH 52 immunosuppressant drug 52 sulfasalazine 52 nucleoside analogs 52 ramipril 52 HI titers 52 Sustained Virological Response 52 detemir 52 statin monotherapy 52 DU #b 52 FTY# 52 #mg ritonavir 52 ORENCIA 52 ganetespib 52 K#N 52 lipid lowering therapies 52 COREG 52 spontaneous bowel movements 52 placebo controlled clinical trials 52 COMBIVIR 52 busulfan 52 Tyrima 52 AZILECT 52 DOXIL 52 AZT 3TC 52 glycosylated hemoglobin levels

Back to home page